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LETTERS TO THE EDITOR
The RBE of low-LET radiations
Dear Sir
It is regrettable that Hunter and Muirhead, in their impressive review of the RBE dependence
on linear energy transfer for low-LET radiations (Hunter and Muirhead 2009), failed to take
mechanistic modelling into account as it provides additional reasons for the clear dependence
of RBE with LET found in the radiobiological studies which they review. It also implies
that the analysis of the epidemiological data made by Hunter and Muirhead is not the most
appropriate for investigating a possible dependence of RBE on the LET of sparsely ionising
radiations. In our opinion, this should have led them to attach much more importance to the
radiobiological data and less to the epidemiology.
Some years ago, we derived a mechanistic model based on DNA double strand breaks to
explain the celullar effects of radiation using a linear-quadratic dose response curve (Leenhouts
and Chadwick 1978). In an extension of that model, we proposed that chromosomal aberrations
are derived from double strand breaks in the DNA chromosome back-bone via a process
of reciprocal recombination (Chadwick and Leenhouts 1978, 1981) which now appears to
be called non-allelic homologous recombination. At that time, a considerable amount of
‘microdosimetry’ research in cellular radiobiology was devoted to the experimental and
theoretical investigation of the RBE-LET relationship. From our point of view, the DNA
double helix, with two sugar phosphate strands separated by some 2 nm, provides a well-
defined, three dimensional target structure for radiation tracks so that the induction of a double
strand break by a single ionising particle track will require two energy deposition events in
about 2 nm along the track close to each of the two strands. The double strand breaks induced
in this way will be proportional with radiation dose (αD) and radiation tracks with ionising
events spaced at about every 2 nm will be most efficient in creating these double strand breaks.
In the case of low-LET radiation, these tracks arise from the softer scattered electrons so that the
biological efficiency of low-LET radiation will be closely related to the proportion of radiation
dose deposited by the softer scattered electron tracks. Clearly, the lower the energy of the
incident gamma or x-ray radiation is, the larger the proportion of dose deposited by the softer
electron tracks will be and, consequently, the larger the biological effectiveness will be. Dose
response curves induced by acute exposure to low LET radiations also exhibit a dose-squared
component (βD2) for double strand breaks arising, in our opinion, from two independently
induced single strand breaks. This dose-squared component does not have a RBE dependence
and will be closely the same for acute exposures to different low-LET radiations, but it does
depend on dose rate and reduces to zero for protracted exposures.
Hunter and Muirhead use a linear-quadratic (αD+βD2) dose effect relationship to analyse
the cytological data and compare the value of the linear coefficients (α) determined for different
low-LET radiations with that determined using hard gamma rays to derive the RBE as a function
of LET. We completely agree with this analysis and would emphasise that the RBE determined
in this way is a maximum RBE which is valid at low doses. The result is as we expect and our
mechanistic model provides a sound explanation for the trend of increasing RBE with LET
found by Hunter and Muirhead for the cytological end-points examined. In their analysis of the
epidemiological data, however, Hunter and Muirhead do not continue to use a linear-quadratic
dose response but instead derive Excess Relative Risks (ERR) which assumes a linear dose
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effect relationship and with which we do not agree.
We expect that the dose effect relationship for an acute exposure to low-LET radiation,
such as leukaemia in the atomic bomb survivors, will have linear-quadratic (LQ) dose kinetics
at low doses but, because the mutated cells leading to cancer must survive to produce the
cancer, the LQ start to the curve will be modified by a survival term and the rising part of the
dose effect relationship will look like a tilted-forward ‘S’. Although this type of curve can be
closely approximated by a straight line to derive ERR, the straight line is not related in any
way to the initial linear slope (α) of the LQ curve which does define the low dose biological
efficiency of the radiation for the determination of RBE. The dose effect relationship for a
chronic exposure which, except for the atomic bomb survivor study, is the situation in many of
the epidemiological studies, will have an initial linear increase in effect that gradually saturates
as a consequence of cell killing. The dose effect relationship for fractionated exposures will
be rather complicated to analyse. The chronic exposure and fractionated exposure cases can
also be approximated by a straight line although, as before, the lines will not be related to the
initial linear slopes (α) which define the low dose biological efficiency. Consequently, the use
of ERR to analyse epidemiological data will obscure the true determination of RBE and we
are not surprised that the analysis of Hunter and Muirhead, even taking the large uncertainties
in the ERR values into account, does not show anything like the trend of RBE with LET that
the cytological data reveal. The epidemiological analysis made by Hunter and Muirhead is
not the appropriate one to examine this problem and should not have been used to force the
conclusions made by them that ‘these data neither support nor disprove the hypothesis that
low- and high-energy x-rays are more effective than high-energy gamma radiation.’ We do not
accept that their analyses permit this conclusion to be drawn.
Hunter and Muirhead have discounted the importance of their results for the cytological end
points by suggesting that ‘there is still some controversy as to whether chromosome aberrations
and transformations are indicative of an increased risk of cancer’. We would recommend them,
and any other doubters, to look at the recent cancer genomics literature and would quote the
first line of a review in the 9 April 2009 issue of Nature, ‘The cancer genome’ which reads ‘all
cancers arise as a result of changes that have occurred in the DNA sequence of the genomes
of cancer cells’ (Stratton, Campbell and Futreal 2009).
In conclusion, it seems to us that the cytological data have been correctly analysed, that
cytological effects are indeed relevant to the induction of cancer, and that the trend of RBE
with LET revealed certainly merits careful consideration in the development of radiological
protection philosophy in the future.
Note added: We would like to add a remark about the effectiveness of tritium because a
similar reasoning to that applied above is relevant. The dichotomy of opinion about the effec-
tiveness of tritium revealed in the Meeting Report on ‘The assessment and control of tritium’s
health risk’ (Bundy and Burtt 2009) in the same issue of Journal of Radiological Protection
arises because one side of the argument is looking at the effectiveness of the low energy beta
particles inducing the effect while the other side takes the ICRP approach via the epidemiology.
The one side can see that the low energy beta particles will be effective mechanistically, the
other sees little reason to accommodate this in the overall philosophy.
References
Bundy K and Burtt J 2009 Report on the CNSC workshop on the assessment and control of tritium’s health risk held
on 8 January 2008 in Ottawa, Canada J. Radiol. Prot. 29 113–17
Letters to the Editor 447
Chadwick K H and Leenhouts H P 1978 The rejoining of DNA double-strand breaks and a model for the formation
of chromosomal aberrations Int. J. Radiat. Biol. 33 517–29.
Chadwick K H and Leenhouts H P 1981 The Molecular Theory of Radiation Biology (Berlin, Heidelberg, New York:
Springer)
Hunter N and Muirhead C R 2009 Review of relative biological effectiveness dependence on linear energy transfer
for low-LET radiations J. Radiol. Prot. 29 5–21
Leenhouts H P and Chadwick K H 1978 The crucial role of DNA double-strand breaks in cellular radiobiological
effects Adv. Radiat. Biol. 7 55–101
Stratton M R, Campbell P J and Fureal P A 2009 The cancer genome Nature 458 719–24
Yours sincerely,
K H Chadwick1 and H P Leenhouts2
1 Cowan Head, Kendal, UK
2 Bennekom, The Netherlands
Reply to ‘The RBE of low-LET radiations’
Dear Sir
We welcome the letter by Dr Chadwick and Dr Leenhouts. Here are our replies to the issues
raised:
The review paper has failed to take mechanistic modelling into account
We agree that mechanistic modelling should provide additional evidence concerning the RBE
dependence on linear energy transfer for low-LET radiations. We did not include such mod-
elling in our paper because few publications have examined the dose-effect relationship for
double strand breaks (DSBs) in human cells using a mechanistic modelling approach. It is
widely accepted that unrepaired or misrepaired DNA DSBs lead to the formation of chro-
mosome aberrations. Hence, we did not think that it was necessary to mention mechanistic
modelling based on DSBs, because there are extensive data on radiation-induced chromosome
aberrations that have been used over many years and cited by bodies such as ICRP (2007) and
BEIR VII (2006).
The analysis conducted of epidemiological data is not the most appropriate for investigat-
ing RBE dependence on LET of sparsely ionising radiations
Drs Chadwick and Leenhouts are concerned that our analysis of epidemiological data dif-
fers from the analysis of cytogenic data, in that we ‘do not continue to use a linear-quadratic
dose-response but instead derive Excess Relative Risks (ERR) which assumes a linear dose
effect relationship.’ The latter part of this argument is incorrect: the use of an ERR model
does not imply that the dose-response relationship has to be linear. In theory, any form
of dose-response model can be considered, for example using the EPICURE software (Pre-
ston et al 1996), and it is certainly possible to fit a linear-quadratic (L-Q) dose-relationship
using an ERR model. Indeed, analyses of solid cancer risk among the Japanese atomic
bomb survivors have adopted such an approach (Preston et al 2003; UNSCEAR 2008).
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However, these analyses show little evidence for a quadratic term in the solid cancer dose-
response, whereas analyses of leukaemia risk—using either an ERR or an Excess Absolute
Risk model (UNSCEAR 2008)—do show evidence for a quadratic term.
The published findings from studies of occupational exposures are generally based on the
fit of a linear, rather than a L-Q dose-response model. The relatively low doses received by
workers mean that these studies generally have low statistical power to detect deviations from
a linear dose-response relationship. At the same time, the narrow range of doses means that
the impact of any quadratic term in the dose response would be low and that the linear term
obtained from fitting an L-Q model should be similar to that based on a linear dose-response
analysis.
The studies of medically exposed groups to which we referred related to cancers of the
thyroid and female breast. In some studies, there was an indication of a flattening in the dose
response at very high doses (>10 Gy). However, pooled analyses of these studies (Ron et al
1995; Preston et al 2002) indicated that the trend in risk with dose is consistent with linearity
and provided no evidence against a linear dose-response model. Hence, we used the ERR
estimates based on a linear model for comparisons both amongst studies of medical exposure
and between these studies and the A-bomb study.
In summary, the comparison of risk estimates based on linear dose-response models is
unlikely to have had a marked influence on our examination of the possible impact of LET.
The review paper casts doubt on whether chromosome aberrations and transformations are
indicative of an increased risk of cancer
We are not disputing that the statement that cancer can arise as a result of changes that have
occurred in the DNA sequence of the genomes of cancer cells. However, the nature of the as-
sociation between the frequency of chromosomal aberrations and the risk of cancer in humans
continues to be controversial.
Whilst some cancers tend to have specific rearrangements—in particular, translocations—
there are valid reasons to doubt whether dicentrics would lead to cancer, because the cells are
unlikely to form colonies.
Associations have been identified between specific stable translocations and certain
cancers. However, whether these aberrations are directly induced by low radiation doses
and whether they are directly causal is still the topic of debate.
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Yours sincerely,
Nezahat Hunter and Colin Muirhead
Health Protection Agency, Centre for Radiation, Chemical and Environmental Hazards,
Chilton, Didcot, Oxon OX11 0RQ, UK
Comment on ‘An etched track detector for short-term
screening measurements of radon’
Dear Sir
We are writing to note that the use of short-term measurements for radon in homes was the
subject of a major DEFRA project, which was published in late 2003 [1]. This report, and
subsequent papers by our group [2–4] gave clear guidance on the accuracy of the track etch,
charcoal and electret detectors for 1-week and 1-month exposures, compared to the standard
3-month exposures. Subsequent analysis of the results prompted our group to recommend
14-day exposures, rather than 7-day exposures, because of potential distortions due to tidal
effects [5].
One important feature of our results, which Ibrahimi and Miles [6] appear to ignore, is that
the 3-month exposure in itself has some uncertainty in estimating the long-term average radon
level (taken as the annual average) which is required to estimate the extent of the long-term
health risk from radon.
The full set of our results, which compared 228 weekly, 228 monthly and 76 three-monthly
readings to the annual average radon level in the tested houses, are reproduced in Table 1. In
our case, a detector measurement at or below the lower bound indicates, with at least 95%
certainty, that the long term average radon level in the houses is below the Action Level; while
a measurement at or above the upper bound indicates, again with at least 95% certainty, that
the long term average radon level in the houses is definitely above the Action Level.
Table 1. Equivocal ranges of various radon detectors exposed for different durations.
1-Week 1-Month 3-Month 1-Week 1-Week
Track-Etch Track-Etch Track-Etch Electret Charcoal
Lower Bound 75 109 112 59 68
Upper Bound 519 478 356 667 522
Our published analysis went on to suggest the circumstances in which a short-term
measurement was of value, as indicated in Table 2. This gives more detail to Ibrahimi and
Miles’ statements about the value of results in low and high radon areas, and we suggest that
the HPA could adopt this methodology, which would obviate the need to always send a set of
three-month exposure detectors to the householder at the same time.
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Table 2. Protocols for use of short-term radon measurements.
Area Initial Test Repeat if equivocal
New Homes in radon affected areas or
< 5% existing houses over Action Level 1-week 1-week
> 5% and < 10% existing houses over Action Level 1-week 3-month
> 10% existing houses over Action Level 3-month 3-month
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Yours sincerely,
A R Denman, C J Groves-Kirkby, P S Phillips and R G M Crockett
School of Applied Sciences, University College Northampton, Boughton Green Road,
Northampton NN2 7AL, UK
Reply to “Comment on ‘An etched track detector for
short-term screening measurements of radon’ ”
Dear Sir
Denman et al suggest that in our paper we appear to ignore the uncertainty on the use of
3-month measurements in estimating long-term average radon concentrations. In fact we have
long recognised such uncertainties—see, for instance Cliff et al (1994) and Miles (2001).
As stated in the paper, measurement results are not reported to the homeowners, but rather
‘all results are corrected to the estimated annual mean radon concentration...using correction
factors based on typical seasonal variation in radon concentrations in UK homes.’
Denman et al further suggest that other work (Phillips et al 2004) provides clearer guidance
on the uncertainties on the results of measurements across the UK with different types of
detectors over different durations. That study reported results of radon measurements of
37 homes over one year in Northamptonshire. We note that the report concluded that ‘St
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Gobain detectors exhibited a large offset, which varied with exposure length.’ These detectors
constituted 65% of the etched-track detectors used in their study. We suggest that this variable
bias in the results makes the conclusions regarding uncertainties on different measurement
durations less reliable. The Health Protection Agency (and its predecessor, the National
Radiological Protection Board) applies quality control measures to prevent such effects from
occurring (Miles et al 2004).
One of the most important factors contributing to uncertainties in estimates of long-term
average concentrations is differences in patterns of seasonal variation between houses. We
are currently analysing the results of a study of 120 homes in five areas of the UK, in which
radon concentrations were measured over eight 3-month periods, to determine how patterns of
seasonal variation in radon concentration differ. We hope to submit this study for publication
within the next few months.
Denman et al also suggest that HPA could avoid the need to issue a set of 3-month detectors
alongside a set of 14-day detectors in some cases, depending on the probability of finding high
radon concentrations in the area where the house to be measured is situated. We agree that a
scheme such as this could limit the number of 3 month detectors issued. However, we believe
that the practice of issuing 3-month detectors alongside 14-day detectors is helpful because
it avoids the need for householders to take further action to start a new measurement in the
case of an equivocal result from the 14-day measurement, since the 3-month measurement is
already under way.
We would like to take the opportunity to point out an error in equation (1) of our paper.
This should read:
Annual mean radon concentration = (C − 4) × (1/[1.645 − 0.063t]) + 4 (1)
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Comments on ‘Impact of tritium around EDF nuclear power
plants’
Dear Sir
We read with interest the paper of Le Guen (2009). The conclusions of Le Guen (2009)
in relation to environmental transport and biological incorporation are very much in line with
those of recent reviews by the Advisory Group on Ionising Radiation (AGIR) of the UK Health
Protection Agency (AGIR 2007) and a related open literature publication (Little and Lambert
2008). Le Guen (2009) remarked on the meta-analysis conducted by Little and Lambert
(2008), and implicitly also the recent review by the AGIR (2007), that ‘the method used by
these authors to ascertain [relative biological effectiveness (RBE)] may be criticised, especially
concerning the method of calculation and of selecting the studies used in the calculation. The
RBE of tritium depends on its location in cells. If tritium is incorporated in DNA precursors
(e.g. thymidine, deoxycytidine, etc), it can deliver doses to the DNA that are more substantial
than if it is located outside a cell nucleus, as is the case after incorporation of HTO. The strategy
is therefore to define the RBE then the weighting factors for these different cases.’
Implicit in this statement is that studies involving tritiated thymidine (3HTdR) should be
considered separately from those involving tritiated water (HTO), and that the RBE for the
former should be higher than the latter. There were only two studies with 3HTdR that met our
quality control criteria and were included in the review (AGIR 2007, Little and Lambert 2008),
namely those of Lambert (1969) and Carr and Nolan (1979); both studies assessed the effects
of 3HTdR and HTO in relation to reference (X or γ ) irradiation. Lambert (1969) assessed
spermatogonial survival in DBA2 male mice injected at the age of 10–12 weeks with HTO or
3HTdR and in a reference group exposed to 200 kVp x-rays. Lambert (1969) ascertained an
RBE of 1.3–1.6 for 3HTdR, or 2.3–2.4 for HTO (Little and Lambert 2008). Carr and Nolan
(1979) assessed testis weight loss in male CBA mice injected intraperitoneally with 0.037–0.74
MBq/gram body mass 3HTdR or 0.37–1.5 MBq/gram body mass HTO at about 100 days of
age, and a reference group exposed to chronically delivered 60Co γ -rays given at a decreasing
dose rate matching the dose rate from HTO (tritium simulator). They ascertained an RBE of
2.07 (95% CI 1.58, 2.56) for 3HTdR, or 1.43 (95% CI 1.06, 1.80) for HTO (Little and Lambert
2008).
These data do not suggest a consistent pattern of variation of RBE by type of tritium
(3HTdR vs HTO) used—in particular the RBE for 3HTdR is not consistently higher than that
of HTO. Taken together with our response (Little and Lambert 2009) to comments made by
Paquet and Métivier (2009) in the same issue, we therefore see no reason to modify our methods
of analysis or conclusions (AGIR 2007, Little and Lambert 2008).
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Yours sincerely,
M P Little1,3 and B E Lambert2
1 Department of Epidemiology and Public Health, Imperial College Faculty of Medicine, Nor-
folk Place, London W2 1PG, UK
2 Department of Radiation Biology, The Medical College of St Bartholomew’s Hospital, Lon-
don, UK (retired)
3 Author to whom all correspondence should be addressed, e-mail: mark.little@imperial.ac.uk
Reply to “Comments on ‘Impact of tritium around EDF
nuclear power plants’ ”
Dear Sir
I would like to express my appreciation for the insights provided by Little and Lambert into
their highly informative publication on retrospective research (Little and Lambert 2008). The
only point of divergence between the paper and the authors’ of these comments is the relative
weight of the results of studies concerning tritiated thymidine when calculating RBE. In their
comments, Little and Lambert go back over the two studies selected for their review and
included in the AGIR 2007 report (AGIR 2007). A notable point is that both these relatively
old studies concern the same organ, i.e. the testicle, and practically the same tissue, responsible
for gametogenesis.
The tissue in question is a fast-regenerating tissue where numerous cells constantly
proliferate. It is therefore very tricky to extend results obtained using this tissue to all
other tissues of an organism, and in particular to more slowly-regenerating tissues. Indeed,
inside the proliferating cells, tritiated thymidine will be directly incorporated into DNA during
replication. In-situ damage to DNA will therefore be substantial and confined to the latter.
Tritium in the form of tritiated water propagates in all cells, regardless of their replicative
status. All cells will then build up damage in all compartments (including the nucleus). It is
therefore hard to imagine a comparable effect between HTO and OBT (h3-thymidine) in all
tissues except some fast-regenerating tissues like the testicle.
It was in an attempt to answer this type of question that we decided, 3 years ago, to support
research into tritium (Saintigny et al 2008) and to resume studies by using tritium in various
forms, i.e. tritiated water (HTO) and tritiated thymidine 3HDTR. For example, research not as
yet published and currently being conducted in Yannick Saintigny’s laboratory (CEA, France)
is showing that the contamination of proliferating cells with HTO or h3-thymidine does not
produce the same biological effects on hematopoiesis.
While Little and Lambert’s results and conclusions should not be called into question per
se, we feel that their extension to the entire organism with a view to defining a total RBE is
still a tricky matter.
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Yours sincerely,
Bernard Le Guen1,3 and Yannick Saintigny2
1 EDF Radiation Protection Council (CRP) and EDF, DPN, Nuclear Power Operation, 1 Place
Pleyel, 93282 Saint Denis, Cedex, France
2 Laboratoire de recherche sur la Réparation et la Transcription dans les cellules Souches
(LRTS), U967 U967—CEA/INSERM/Universities Paris VII & XI, 18 route du Panorama, 92
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3 Author to whom all correspondence should be addressed, e-mail: bernard.le-guen@edf.fr
Comments on ‘Are the risks from tritium exposures being
underestimated?’
Dear Sir
We read with interest the paper of Paquet and Métivier (2009). The main conclusions are very
much in line with those of recent reviews by the Advisory Group on Ionising Radiation of
the UK Health Protection Agency (AGIR 2007) and two related open literature publications
(Little and Lambert 2008, Little and Wakeford 2008). Paquet and Métivier (2009) remarked
on the meta-analysis conducted by Little and Lambert (2008) (incorporated also in AGIR
(2007)) that ‘the method used by these authors to define a standard RBE may lay itself open
to criticism, particularly as regards the calculation method and the selection of studies used
in this calculation. In fact, the ICRP—in its latest publication—preferred to use all published
data as a basis, and to estimate the range of predominant RBEs. It concluded that the majority
of RBEs, all effects combined, range between 1 and 3 with regard to gamma rays and between
1 and 1.5 with regard to x-rays (ICRP 2007).’
For certain of the experimental studies, in particular those of Gragtmans et al (1984),
Matsuda et al (1986), Zhou et al (1986), Satow et al (1989), Kamiguchi et al (1990a, b), Tanaka
et al (1994), Johnson et al (1995) and Kozlowski et al (2001), where the original statistical
analysis was suboptimal, or in which the relevant quantity, RBEmax , was not estimated, Little
and Lambert (2008) attempted re-analysis; for some studies (Gragtmans et al (1984), Johnson
et al (1995)), when the re-analysed results were close to the original estimates the original
estimates were employed for the purposes of the meta-analysis. We judge that to do as we did
was better than to use the original analysis, which was in many cases suboptimal, for example
using the wrong error structure (e.g., assuming normal rather than binomial or Poisson errors),
which would have yielded the wrong uncertainty range. The method used by Little and Lambert
(2008) to aggregate risks, the best linear unbiased estimator (BLUE), is a standard statistical
technique, with well known optimality properties (Mood et al 1974). In particular, among
linear unbiased combinations of estimators it has the lowest variance (Mood et al 1974).
The implicit preference of Paquet and Métivier (2009) for considering all studies without
regard to experimental quality (which was not in fact what ICRP (2007) did) we regard as
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scientifically unjustified. The main selection criteria for our meta-analysis were that the report
had to have concurrent X- or γ -irradiated reference group, and that estimates of RBEmax be
given (or computable from the published data) together with uncertainties. The dangers of
using non-concurrent controls are well known—it was judged that inclusion of studies with
non-concurrent controls in the meta-analysis would lead to possible bias. As above, we gave
priority to use of an inverse-variance weighted (BLUE) approach to combine estimates and
uncertainties from individual studies in developing pooled estimates of RBEmax . The reason
for doing this was to obtain statistical uncertainties in aggregate estimates. We took the view
that a parameter estimate without an associated estimate of uncertainty is of little use, and in
particular cannot be used to derive an aggregate measure of RBEmax and its uncertainty.
In summary, whilst we do not substantially differ from the conclusions of Paquet and
Métivier (2009) we judge that the techniques of study selection, and in some cases re-analysis,
performed by AGIR (2007) and Little and Lambert (2008) are fully justified.
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Comment on “Response to ‘More on the risk of cancer among
nuclear workers’ ”
Dear Sir
In the June issue of this journal, Professor Simmons (Simmons 2009) responded to an
editorial published in the previous issue (Wakeford 2009). This editorial was prompted by
the publication in the British Journal of Cancer earlier this year of the 3rd analysis of the
National Registry for Radiation Workers (NRRW) (Muirhead et al 2009). I shall not address
Professor Simmons’ comments on the more general points made in the editorial. However, I
would like to respond to his comments that relate specifically to the NRRW analysis.
First, Professor Simmons queries the existence of a ‘healthy worker effect’ (HWE) in the
NRRW, based on findings for radiologists. It is hard to think why the evidence for or against a
HWE in radiologists would affect the interpretation of findings for the NRRW, which includes
very few workers from the medical sector. Standardised mortality ratios (SMRs) below 100%
have been observed in various occupational groups, including workers in non-nuclear sectors
(Fox and Collier 1976) and even among non-radiation workers employed in the nuclear sector
(e.g. Atkinson et al 2004). Furthermore, SMRs that are statistically significantly less than 100
were seen in the NRRW not only for cancer but also for various non-malignant diseases and
for the category of all accidents and violence (Muirhead et al 2009). Consequently, it is very
clear that there is a HWE in the NRRW.
Secondly, in discussing the NRRW analysis of cancer risk in relation to external radiation
dose (Muirhead et al 2009), Professor Simmons comments on the relatively small number of
data points that are statistically significantly greater than a relative risk of 1. However, it should
be borne in mind that as data are divided more finely, the statistical precision of individual
data points will be reduced. Our objective was not to analyse individual data points, but rather
to assess the evidence for any trends in risk with dose in the NRRW and to see whether this
was consistent with trends estimated from the Japanese A-bomb survivors. Not only did we
find statistically significant trends with dose in both mortality and incidence for non-CLL
leukaemia and for cancers other than leukaemia (with or without lung and pleural cancers),
but also these trends were highly consistent with the trends estimated at low doses from the
A-bomb study. Thus our findings do strengthen the evidence for raised cancer risks associated
with occupational radiation exposures.
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Yours sincerely,
Colin Muirhead
Health Protection Agency, Radiation Protection Division, Chilton, Oxon OX11 0RQ, UK
Comment on ‘Mammography—oncogenecity at low doses’
Dear Sir
We read with considerable interest the paper by Heyes et al entitled ‘Mammography—
oncogenecity at low doses’ recently published in your journal [1].
In their paper, the Heyes et al assert that ‘evidence highlighting the increase in relative
biological effectiveness (RBE) of mammography x-rays to a range of x-ray energies implies
that the risks of radiation-induced breast cancers for mammography x-rays are potentially
underestimated by a factor of four.’ They then extrapolate their alarming conclusion by stating
‘the risk/benefit analysis (of the UK NHS breast screening programme), however, implies the
need for caution for women screened under the age of 50, and particularly for those with a
family history (and therefore a likely genetic susceptibility) of breast cancer.’
The authors do note that there is potentially some uncertainty in their conclusion by
acknowledging that ‘recent low dose in vitro data have indicated a potential suppressive effect
at very low dose rates and doses.’ However, they then apparently discount the uncertainty and
this suppressive effect by stating that ‘whilst mammography is a low dose exposure, it is not a
low dose rate examination, and protraction of dose should not be confused with fractionation.’
In this letter, we wish to point out some data, not noted by the authors, that calls into
question their conclusions. The suppressive effect to which the authors refer is the data of
Azzam et al [2] and the data of Redpath et al [3–5] showing that low doses of gamma radiation
or x-rays reduce the neoplastic transformation frequencies of a mouse cell system (C3H 10T1/2)
and a human hybrid cell system (CGL1) to values below that of their spontaneous frequencies.
This latter system was the same cell system used by Heyes et al [1] to determine their quoted
RBE values. Of particular importance to the question at hand (and noted by the authors)
is data showing that this suppressive effect is also seen with low doses of mammographic
energy x-rays [6]. Like the study of Heyes et al [7], these experiments were carried out at
high dose-rate as were the experiments with fluoroscopy energy x-rays [5]. The earlier studies
of Azzam et al [2] and Redpath et al [3, 4] used low dose-rate for the low dose exposures.
Subsequent studies at much lower dose-rates [8, 9] also show a suppressive effect at low doses.
In summary, the collective experience is that suppression of neoplastic transformation in vitro
by low doses (<100 mGy) occurs over a wide range of dose rates (0.1–>1000 mGy/min). It is
perhaps important to note that such protective effects of low doses of radiation have apparently
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been tightly conserved throughout evolutionary history [10]. Recently the nature of the various
protective mechanisms induced by low doses, and their influence on radiation risk predictions
and outcomes, has been reviewed [11].
In their paper, the authors further elaborate on the reason for their dismissal of these
apparently ubiquitous, protective cellular responses. They ‘...suggest that the J-shaped model
of transformation suppression at low doses may be compromised by this significantly higher
background transformation rate, and that the observations of Ko et al [6] should be confirmed
under experimental conditions in which the spontaneous transformation frequency is much
lower before such models are adopted for radiological protection purposes.’
Apparently the authors are unaware that Redpath and Elmore have considered the impact
of background transformation rate on the shape of the dose response curve [12]. In that
publication, they combined all their data for low-LET radiation sources, even though, as
they acknowledge, the data are for radiation sources of different energy that potentially have
different biological effectiveness. Redpath and Elmore pointed out that ‘the experiments were
performed over a period of years using different batches of serum, and since serum batch is
well known to influence background frequency, this combination had to be done for two groups
separated by level (‘low’ and ‘high’) of spontaneous background frequencies.’ Even though the
spontaneous background frequency of transformation varied by more than 2-fold in the ‘low’
and ‘high’ cases, transformation frequency was clearly suppressed in both instances, at doses
<100 mGy. Indeed, the mean of the ‘low’ values was 3.10±0.2×10−5, a value essentially the
same as that of 2.8 ± 0.4 × 10−5 seen by Heyes et al [7]. This analysis contradicts the current
suggestion of Heyes et al [1] that high spontaneous transformation frequency compromises
the general conclusion that low doses suppress rather than increase risk.
We would additionally point out that these protective effects of low doses, and dose
thresholds for harm, are not confined to cells in culture, but have been repeatedly observed
in cancer studies in animals [13, 14]. Additionally, those observations have been repeated in
mice that were cancer prone for genetic reasons [15, 16], a point bearing directly on the authors
special concern for ‘those with a family history (and therefore a likely genetic susceptibility)
of breast cancer.’
In summary, for the reasons stated, we believe that the existing data do not support the
somewhat alarming conclusions of Heyes et al [1], not withstanding apparent RBE increases
for mammographic x-rays seen at doses higher than 200 mGy.
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